291 related articles for article (PubMed ID: 32411795)
1. Overexpression of an Immune Checkpoint (CD155) in Breast Cancer Associated with Prognostic Significance and Exhausted Tumor-Infiltrating Lymphocytes: A Cohort Study.
Li YC; Zhou Q; Song QK; Wang RB; Lyu S; Guan X; Zhao YJ; Wu JP
J Immunol Res; 2020; 2020():3948928. PubMed ID: 32411795
[TBL] [Abstract][Full Text] [Related]
2. PD‑L1/PD‑1 blockade in breast cancer: The immunotherapy era (Review).
Li CJ; Lin LT; Hou MF; Chu PY
Oncol Rep; 2021 Jan; 45(1):5-12. PubMed ID: 33416128
[TBL] [Abstract][Full Text] [Related]
3. The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.
Barroso-Sousa R; Barry WT; Guo H; Dillon D; Tan YB; Fuhrman K; Osmani W; Getz A; Baltay M; Dang C; Yardley D; Moy B; Marcom PK; Mittendorf EA; Krop IE; Winer EP; Tolaney SM
Ann Oncol; 2019 Apr; 30(4):575-581. PubMed ID: 30753274
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of CD155 is associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in the breast cancer microenvironment.
Wang RB; Li YC; Zhou Q; Lv SZ; Yuan KY; Wu JP; Zhao YJ; Song QK; Zhu B
World J Clin Cases; 2020 Dec; 8(23):5935-5943. PubMed ID: 33344592
[TBL] [Abstract][Full Text] [Related]
5. Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up.
Lundgren C; Bendahl PO; Ekholm M; Fernö M; Forsare C; Krüger U; Nordenskjöld B; Stål O; Rydén L
Breast Cancer Res; 2020 Dec; 22(1):140. PubMed ID: 33357231
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 Acts as a Promising Immune Marker to Predict the Response to Neoadjuvant Chemotherapy in Breast Cancer Patients.
Du Q; Che J; Jiang X; Li L; Luo X; Li Q
Clin Breast Cancer; 2020 Feb; 20(1):e99-e111. PubMed ID: 31521537
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients.
Yoshikawa K; Ishida M; Yanai H; Tsuta K; Sekimoto M; Sugie T
PLoS One; 2021; 16(6):e0253176. PubMed ID: 34115802
[TBL] [Abstract][Full Text] [Related]
8. CTLA-4 Expression and Its Clinical Significance in Breast Cancer.
Kern R; Panis C
Arch Immunol Ther Exp (Warsz); 2021 Jun; 69(1):16. PubMed ID: 34148159
[TBL] [Abstract][Full Text] [Related]
9. Metaplastic breast cancer: an old histotype but a current therapeutic problem.
Gadaleta-Caldarola G; Nenna R; Lanotte L; Doronzo A; Gadaleta-Caldarola A; Roma I; Lombardi L; Infusino S
Future Oncol; 2021 Mar; 17(8):955-963. PubMed ID: 33538176
[TBL] [Abstract][Full Text] [Related]
10. Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis.
Duchnowska R; Pęksa R; Radecka B; Mandat T; Trojanowski T; Jarosz B; Czartoryska-Arłukowicz B; Olszewski WP; Och W; Kalinka-Warzocha E; Kozłowski W; Kowalczyk A; Loi S; Biernat W; Jassem J;
Breast Cancer Res; 2016 Apr; 18(1):43. PubMed ID: 27117582
[TBL] [Abstract][Full Text] [Related]
11. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
[TBL] [Abstract][Full Text] [Related]
12. Predicting the immune landscape of invasive breast carcinoma based on the novel signature of immune-related lncRNA.
Shen S; Chen X; Hu X; Huo J; Luo L; Zhou X
Cancer Med; 2021 Sep; 10(18):6561-6575. PubMed ID: 34378851
[TBL] [Abstract][Full Text] [Related]
13. Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation.
Segovia-Mendoza M; Romero-Garcia S; Lemini C; Prado-Garcia H
J Immunol Res; 2021; 2021():6668573. PubMed ID: 33506060
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
15. High expression of E-cadherin and Ki-67 associated with functional/dysfunctional phenotypes of tumor-infiltrating lymphocytes among Chinese patients with operable breast cancer.
Wang R; Shi F; Zhao L; Zhao Y; Wu G; Song QK
J Int Med Res; 2018 Dec; 46(12):5219-5227. PubMed ID: 30318965
[TBL] [Abstract][Full Text] [Related]
16. Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer.
Wei L; Wu N; Wei F; Li F; Zhang Y; Liu J; Ren X
Int Immunopharmacol; 2020 Jul; 84():106506. PubMed ID: 32330866
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
[TBL] [Abstract][Full Text] [Related]
18. The Role of CXCL13 and CXCL9 in Early Breast Cancer.
Razis E; Kalogeras KT; Kotsantis I; Koliou GA; Manousou K; Wirtz R; Veltrup E; Patsea H; Poulakaki N; Dionysopoulos D; Pervana S; Gogas H; Koutras A; Pentheroudakis G; Christodoulou C; Linardou H; Pavlakis K; Koletsa T; Pectasides D; Zagouri F; Fountzilas G
Clin Breast Cancer; 2020 Feb; 20(1):e36-e53. PubMed ID: 31699671
[TBL] [Abstract][Full Text] [Related]
19. Emerging immune gene signatures as prognostic or predictive biomarkers in breast cancer.
Kwon MJ
Arch Pharm Res; 2019 Nov; 42(11):947-961. PubMed ID: 31707598
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]